Gene: BRAF ×
Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913338
rs121913338
BRAF
C 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121913364
rs121913364
BRAF
C 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121913365
rs121913365
BRAF
G 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs397507484
rs397507484
BRAF
G 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs397516896
rs397516896
BRAF
G 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs397516896
rs397516896
BRAF
T 0.700 GeneticVariation CLINVAR Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. 26619011

2016
dbSNP: rs121913348
rs121913348
BRAF
T 0.700 GeneticVariation CLINVAR Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 25157968

2014
dbSNP: rs121913348
rs121913348
BRAF
T 0.700 GeneticVariation CLINVAR Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. 18060073

2007
dbSNP: rs113488022
rs113488022
BRAF
0.030 GeneticVariation BEFREE Here we present an unusual case of a patient with TP53-mutated chronic lymphocytic leukemia (CLL) treated with a PI3Kδ inhibitor evolving to clonally related Langerhans cell histiocytosis (LCH) with acquired BRAF V600E and STK11 mutations and loss of expression of PAX-5 and other examined B cell markers. 31317311

2019
dbSNP: rs121913377
rs121913377
BRAF
0.030 GeneticVariation BEFREE Here we present an unusual case of a patient with TP53-mutated chronic lymphocytic leukemia (CLL) treated with a PI3Kδ inhibitor evolving to clonally related Langerhans cell histiocytosis (LCH) with acquired BRAF V600E and STK11 mutations and loss of expression of PAX-5 and other examined B cell markers. 31317311

2019
dbSNP: rs113488022
rs113488022
BRAF
0.030 GeneticVariation BEFREE We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leukemias/small lymphocytic lymphomas (CLLs/SLLs), and 21 plasma cell neoplasms (PCNs) for BRAF V600E expression by IHC. 26071465

2015
dbSNP: rs121913377
rs121913377
BRAF
0.030 GeneticVariation BEFREE We analyzed 121 cases, including 26 HCLs, 52 non-HCL splenic lymphomas, 22 chronic lymphocytic leukemias/small lymphocytic lymphomas (CLLs/SLLs), and 21 plasma cell neoplasms (PCNs) for BRAF V600E expression by IHC. 26071465

2015
dbSNP: rs113488022
rs113488022
BRAF
0.030 GeneticVariation BEFREE Although present at a low frequency, the finding of BRAF V600E has biological and clinical implications for CLL and PLL. 22230299

2012
dbSNP: rs121913377
rs121913377
BRAF
0.030 GeneticVariation BEFREE Although present at a low frequency, the finding of BRAF V600E has biological and clinical implications for CLL and PLL. 22230299

2012